Pharming Group Long Term Debt 2013-2021 | PHGUF

Pharming Group long term debt from 2013 to 2021. Long term debt can be defined as the sum of all long term debt fields.
Pharming Group Annual Long Term Debt
(Millions of US $)
2020 $147
2019 $5
2018 $44
2017 $67
2016 $45
2015 $14
2014 $1
2013 $2
2012 $3
Pharming Group Quarterly Long Term Debt
(Millions of US $)
2021-03-31 $149
2020-12-31 $158
2020-03-31 $139
2019-03-31 $41
2018-03-31 $62
2017-03-31 $36
2016-03-31 $12
2015-03-31 $1
2014-03-31 $2
2013-03-31 $2
2012-12-31 $3
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $0.564B $0.212B
Pharming Group NV develops innovative therapeutics for the treatment of genetic disorders, specialty products for surgical indications and nutritional products. The advanced technologies of the Company include innovative and validated platforms for the production of protein therapeutics, technology and processes for the purification and formulation of its products. Its primary product Ruconest (R) is a recombinant human C1 inhibitor approved for the treatment of angioedema attacks in patients with hereditary angioedema in the European Union countries, Norway, Iceland and Liechtenstein. Pharming Group NV is headquartered in Leiden, the Netherlands.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $129.683B 8.63
Bio-Rad Laboratories (BIO.B) United States $21.975B 46.83
QIAGEN (QGEN) Netherlands $11.773B 19.94
Biohaven Pharmaceutical Holding (BHVN) United States $8.738B 0.00
Emergent Biosolutions (EBS) United States $2.722B 6.57
Arcus Biosciences (RCUS) United States $2.455B 0.00
Myovant Sciences (MYOV) United Kingdom $1.915B 0.00
ADC Therapeutics SA (ADCT) Switzerland $1.755B 0.00
Zymeworks (ZYME) Canada $1.208B 0.00
Ambrx Biopharma (AMAM) United States $0.470B 0.00
SQZ Biotechnologies (SQZ) United States $0.342B 0.00
Enzo Biochem (ENZ) United States $0.183B 18.00